FDA Brief

Warning letters Drugs

FDA warning letter to

Chemspec Chemicals Private Limited

High riskIssued Dec 23, 2025Posted Jan 13Center for Drug Evaluation and Research (CDER)

FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.

What happened

FDA inspected Chemspec's drug manufacturing facility in Navi Mumbai, India, from July 28 to August 1, 2025. Investigators found that the company made and released API lots without batch manufacturing records, distributed lots without documented quality unit review and release, discarded original executed records, and let production staff document past steps after the fact. FDA said the response of August 21, 2025, was inadequate and noted similar deviations were cited in an untitled letter dated February 5, 2025.

What FDA found

  1. The quality unit released API lots without creating or keeping batch production records, and only investigated after FDA investigators cited it.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7
  2. Multiple API lots were distributed without any documented quality unit review and release.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7
  3. Two separate logbooks for issuing lot numbers produced two batch records for the same lot number, and two batch records in production had no control number or issuance record.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7
  4. Original CGMP records, including many pages of executed batch records and a lab testing record, were discarded and replaced with blank forms without a documented investigation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. Production staff who had not performed or witnessed earlier operations wrote weights, solvent amounts and temperatures into API batch records after the fact instead of at the time of the step.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. FDA had cited similar CGMP deviations in an untitled letter dated February 5, 2025, showing that management oversight and control are inadequate.

What FDA wants

FDA tells Chemspec to reply in writing within 15 working days with a full remediation plan for the quality unit, a corrective and preventive action plan for documentation, a data integrity investigation with root causes, a risk assessment for patients, and a management strategy. FDA strongly recommends hiring a qualified consultant to help.

Who should pay attention

  • US finished-dose manufacturers that buy APIs or intermediates from this site
  • brands and distributors sourcing APIs from Indian suppliers
  • quality and supply chain teams qualifying API suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk